期刊文献+

骨质疏松性骨折药物治疗的临床观察 被引量:5

The Observation of Osteoporotic Fractures Treated by Medicine
下载PDF
导出
摘要 目的探讨应用药物治疗骨质疏松性骨折的疗效。方法对60例患者给予补钙治疗,同时服用骨化三醇+降钙素。于用药半年、1年后通过拍摄胸腰椎片、骨密度检查,以及骨折发生情况评价疗效。结果治疗前60例患者的腰椎骨密度值平均为(0.679±0.100),治疗半年后平均(0.780±0.110),治疗后1年平均为(0.765±0.099)。治疗1年后及半年后骨密度值较治疗前差异有统计学意义(P<0.01),治疗期间未发生脊柱其他节段压缩骨折。结论降钙素+维生素D+钙剂治疗骨质疏松性脊柱压缩性骨折,能有效缓解疼痛,增加骨密度。 Objective To observe the curative effect of medicine on treating osteoporotic fractures. Methods All 60 patients were given calcium supplements treatment with taking calcitriol and calcitonin. To value the curative effect of the patients, who’re treated with medicine for 6 months, by X-ray, Bone Mineral Density(BMD) measurement, and fracture condition. Results Before and after 6 months as well as 12 months treatment, the patients’ BWD were(0.679±0.100),(0.780±0.110) and(0.765±0.099) individually on average. The result shows, after 6 or 12 months treatment, the BMD of patients increases significantly (P0.01). There was no new osteoporotic thoracolumbar vertebral compressive fracture occurred on patients. Conclusion Treating the osteoporotic thoracolumbar vertebral compressive fractures with calcitonin, calcium carbonate and calcitriol can relieve pain and improve BMD.
出处 《中外医疗》 2013年第12期105-105,107,共2页 China & Foreign Medical Treatment
关键词 骨质疏松 药物 骨折 骨密度 Osteoporosis Medicine Fracture BMD
  • 相关文献

参考文献6

二级参考文献26

  • 1娄明武,范义,朴荣日,胡卫东,王秀荣.骨质疏松与病理性骨折的相关性研究[J].中国骨质疏松杂志,2006,12(4):330-332. 被引量:8
  • 2RYMER J, ROBINSON J, FOGELMAN I. Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausa| bone loss [ J ] .Osteoporos Int, 2001,12 (6) : 478-483.
  • 3BROWN J P, KENDLER D L, McCLUNG M R, et al. The ef- ficacy and tolerability of risedronate once a week for the treat- ment of postmenopausal osteoporosis [J].Calcif Tissue Int, 2002,71 (2) : 103-111.
  • 4DE GROEN P C, LUBBE D F, HIRSCH L J, et al. Esophagi- tis associated with the use of alendronate [J ].N Engl J Med, 1996,335(14): 1016-1021.
  • 5HODSMAN A B, KISIEL M, ADACHI J D, et al. Histomor- phometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH (1-34) therapy in women with severe osteoporosis [J].Bone, 2000,27(2) :311-318.
  • 6YANG N N, VENUGOPALAN M, HARDIKAR S, et al. I- dentification of an estrogen response element activated by metabolites of 17 β-estradiol and raloxifene [J].Science, 1996,273 (5279) : 1222- 1225.
  • 7LINDSAY R, COSMAN F, LOBO R A, et al. Addition of al- endronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial [ J ]. J Clin Endocrinol Metab, 1999,84 (9) : 3076-3081.
  • 8JOHNELL O, SCHEELE W, LU Y, et al. Effects of raloxifene (RLX) ,alendronate (ALN) and RLX + ALN on bone mineral density (BMD) and biochemical markers of bone turnover in postmenopausal women with osteoporosis [J].J Bone Miner Res, 1999,14(Suppl 1) :S157.
  • 9COSMAN F, NIEVES J, WOELFERT L, et al. Parathyroid hormone added to established hormone therapy: effects on ver- tebral fracture and maintenance of bone mass after parathyroid hormone withdrawal [ J ] .J Bone Miner Res, 2001 , 16 ( 5 ) : 925- 931.
  • 10Kains JA,Blaek D,Cooper C,et al. International osteoporosis founda- tion and the national osteoporosis foundation, USA. A new approach to the development of assessment guidelines for ostenporosis [J]. Osteoropros Int, 2002,13(7) : 527-536.

共引文献55

同被引文献28

引证文献5

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部